论文部分内容阅读
WR-2721做为辐射或化疗防护剂以及降低钙的药物正在进行临床试用。作者用电化学高效液相色谱技术测定血液和组织中的WR-2721和它的含巯基代谢产物WR-1065,和对称性二硫化物WR-33278。给13个肿瘤患者快速静脉注射WR-2721 150mg/m~2,给药后0、0.5、1、2、2.5、3、4、6、8、12、15、20、30、45分钟取血。在冰冷条件下血液收集在EDTA管,保存在酸性溶液中。作者实验空WR-1065和WR-33278的血液回收率各为104％和98％,而在小鼠肝脏中回收率分别为98％和95％。收集6个病人的尿液,贮存在-70℃备用。用Holford方法测定药物代谢动力学模型及其参数值。
WR-2721 is undergoing clinical trials as a radiation or chemopreventive agent and a drug that reduces calcium. The authors used electrochemical high performance liquid chromatography to determine WR-2721 and its thiol-containing metabolite WR-1065, and the symmetrical disulfide WR-33278 in blood and tissues. Rapid intravenous injection of WR-2721 150 mg / m ~ 2 was given to 13 tumor patients and blood was taken at 0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 15, 20, 30, 45 minutes after administration . Blood is collected in EDTA tubes under ice-cold conditions and stored in acidic solution. The authors found that the blood recoveries of experimental empty WR-1065 and WR-33278 were 104% and 98%, respectively, whereas the recoveries in mouse livers were 98% and 95%, respectively. Urine from 6 patients was collected and stored at -70 ° C until use. Pharmacokinetic model and its parameter values were determined by Holford method.